

From the North Florida Thyroid Center, Tallahassee, Florida.

Address correspondence to Celeste B. Hart, MD, North Florida Thyroid Center, 1705 South Adams St., Tallahassee, FL 32301-5621. E-mail: hart@thyroidcenter.com.

C.B.H. has received honoraria from Sanofi Aventis, Novo Nordisk, GlaxoSmithKline, Takeda, and Eli Lilly.

DOI: 10.2337/dc06-0262

© 2006 by the American Diabetes Association.

References

1. Adams AS, Zhang F, Mah C, Grant RW, Kleinman K, Meigs JB, Ross-Degnan D: Race differences in long-term diabetes management in an HMO. *Diabetes Care* 28:2844–2849, 2005
2. National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources: *The Management of Sickle Cell Disease*. 4th ed. Washington, DC, 2002 (NIH publ. no. 02-2117)
3. Ashley-Koch A, Yang Q, Olney RS: Sickle hemoglobin allele and sickle cell disease: a HuGE review. *Am J Epidemiol* 151:839–845, 2000
4. Bry L, Chen PC, Sacks DB: Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. *Clin Chem* 47:153–163, 2001
5. Factors that interfere with GHB (HbA1c) test results [article online], 2004. Available from <http://web.missouri.edu/~diabetes/ngsp/index.html>. Accessed 22 January 2006
6. American Diabetes Association: Standards of medical care in diabetes—2006. *Diabetes Care* 29 (Suppl. 1):S4–S42, 2006

Race Differences in Long-Term Diabetes Management in an HMO

Response to Hart

We read Dr. Hart's (1) response to our article with great interest. The issue of racial differences in the presence of variant hemoglobins that may affect HbA_{1c} (A1C) test results is certainly an important one. Ours (2) was a retrospective analysis using electronic medical record data that did not contain information on either the presence of sickle hemoglobin or the results of patient self-monitoring of blood glucose (SMBG)

testing. However, because we found persistent differences in A1C lab values by race, even when controlling for individual-level A1C at baseline in our multivariate analyses, we do not believe the presence of sickle hemoglobin in 8% of our population would eliminate the racial disparities we observed. Still, the issue of measurement raised by Dr. Hart is worthy of discussion. Because of possible variations in the calculation of A1C over time, we ran several diagnostic tests on our A1C measures to test for systematic differences in measurement over time by race. While we did not identify shifts in A1C by race, we did find a shift in A1C values for the entire cohort midway through our study period due to a change in the calculation of A1C by an external vendor. As stated in our article (2), we adjusted for this change using statistical techniques and found no race-based differences in the effect of this adjustment.

We agree with Dr. Hart that a combination of patient SMBG and A1C results represents a better standard for assessing actual control. Unfortunately, rates of SMBG testing in this population were below optimal and were particularly low for black patients. Furthermore, information from patient SMBG is not consistently recorded in the medical record. For this reason, we are now exploring strategies for increasing SMBG among all diabetic patients, especially black patients. We are also exploring interventions that would incorporate patient data from both lab A1C testing and SMBG values in clinical decisions.

ALYCE S. ADAMS, PHD¹

FANG ZHANG, PHD¹

CONNIE MAH TRINACTY, MS¹

RICHARD W. GRANT, MD, MPH²

KEN KLEINMAN, SCD¹

JAMES B. MEIGS, MD, MPH²

DENNIS ROSS-DEGNAN, SCD¹

From the ¹Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts; and the ²General Medicine Unit, Massachusetts General Hospital, Boston, Massachusetts.

Address correspondence to Dr. Alyce S. Adams, PhD, Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, 133 Brookline Ave., 6th Floor, Boston, MA 02215. E-mail: aadams@hms.harvard.edu.

DOI: 10.2337/dc06-0430

© 2006 by the American Diabetes Association.

References

1. Hart CB: Race differences in long-term diabetes management in an HMO (Letter). *Diabetes Care* 29:1461–1462, 2006
2. Adams AS, Zhang F, Mah C, Grant RW, Kleinman K, Meigs JB, Ross-Degnan D: Race differences in long-term diabetes management in an HMO. *Diabetes Care* 28:2844–2849, 2005

Testing the Accelerator Hypothesis: Body Size, β -Cell Function, and Age at Onset of Type 1 (Autoimmune) Diabetes

Response to Dabelea et al.

The contribution by Dabelea et al. (1) to the growing debate on the accelerator hypothesis is an important one, but I wonder if there is a confounder that has not been accounted for in the reasoning. The report revolves principally around Fig. 2, which shows, after appropriate adjustments, a clear inverse relationship between age at diagnosis and BMI (the acceleration predicted) among those whose fasting C-peptide (FCP) levels lay below the median, but none among those whose FCP lay above. The difference is interpreted to mean that any relationship to insulin resistance applies only to a subset of type 1 diabetic children with low β -cell reserve.

The accelerator hypothesis argues that “type 1 and type 2 diabetes are the same disorder of insulin resistance, set against different genetic backgrounds” (2). It predicts a general inverse relationship between BMI (surrogate for insulin resistance) and age at diagnosis and identifies three accelerators that determine the rate at which the β -cell mass declines during life: constitution (genes/gestation), insulin resistance (lipotoxicity and antigenicity), and immune response (HLA) genotype (response to insulin resistance-induced antigenicity).

The one adjustment that was not made to the regressions in Fig. 2 of Dabelea et al.'s report may be the crucial one: the HLA genotype. Those children who